Back to EZorb Newsletter Index

EZorb

  

EZORB MONTHLY NEWSLETTER OCT 28, 2016

In this issue:

 

1. Share Success: Letters From Readers
2. Research News: Genetically Low Lipids Tied To Higher Diabetes Risk
3. Useful Links
4. Calcium Absorption Test
5. What Are Others Saying About EZorb and Marvlix?

1. Share Success: Letters From Readers 


Letter I: From Julie S.

Received at sharesuccess @ ezorbonline.com Aug 29 at 7:05 AM PDT

(Unedited)

 

Hi,

I wish I could help every person I see who suffers from physical movement; I want to shout to the world how ezorb had helped me on my osteoporosis.

I never bothered go back again to my arthritis doctor as the ezorb calcium aspartate anhydrous helped me daily to move and to have strong bones. I can still carry groceries on both hands without a problem. The aches in my fingers disappeared. I can walk, climb stairs and do yoga without a problem. I can follow the different poses in yoga without restriction.

I just turned 70 this July and my son is amazed that at this age, I can move about pretty quick and is able to do long and fast walks with him. He asked me what do I do. I told him the Ezorb calcium tablets that I take daily which keeps me energetic, moving and no pain.

Ezorb calcium aspartate has maintained my mobility and ease in being able to do my chores and other routine. It keeps me going. What a relief that I found this calcium.

I dreaded the side effects of the arthritis/osteoporosis that I was being given by my doctor. From reading it I know that I will suffer side effects that will hamper me later on.

Being in this situation, I have to do something and not let osteoporosis damage me further in my old age. I want to be able to stay young, moving and most of all without pain. I continue to take it daily and make sure not to miss my daily intake.

I continue to spread the goodness of this supplement to everyone I see out there. I do not have any embarrassment or second thoughts in giving my story on how this capsules have helped me daily.

I know at times they look me funny and I do not know if they follow what I say to look it up in the internet and read the testimonials to your product. It is all up to them. I cannot bear to see other people suffering in their mobility out there knowing something is out there that can help them too.

I am under 3 medications at this time but continue to take Ezorb calcium as I am convinced Ezorb has no side effects. I continue to enjoy my life everyday without pain.

Julie S.


Letter II: From Audrey

Received at Testimonial Submit Form Thursday, July 28, 2016 at 08:09:10

(Unedited)

 

Hi, my name is Audrey.

I was diagnosed with osteoporosis two years ago and my doctor prescribed Fosamax D. I didn't take it because my friends had all lost teeth taking it. Instead I started Ezorb religiously.

My doctor didn't want to hear about Ezorb (and believe me I tried to tell her). A year and a half later I begged for a bone density test, and guess what! I went from osteoporosis to osteopenia! I am 67 and that just doesn't happen!

My doctor didn't want to hear about Ezorb but the other doctors in the practice did!


From the Desk of EZorb Newsletter Editor:

 
This newsletter is now read by over 95,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's quality of life. Your continuous support will be greatly appreciated by tens of thousands who have been suffering and would continuously suffer, without your help! Please email your story to sharesuccess @ ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public. If your testimonial is selected for publication, you will receive a generous gift to show our appreciation of your effort.


2. Research News: Genetically Low Lipids Tied To Higher Diabetes Risk

 

A meta-analysis published in JAMA shows that mutations linked to reduced low-density lipoprotein (LDL) cholesterol levels are associated with an increased risk of diabetes.

Nicholas Wareham (University of Cambridge, UK) and team found that LDL cholesterol-lowering mutations located in and around the NPC1L1 gene, which encodes the molecular target of ezetimibe, conferred a reduced risk of coronary artery disease (CAD), but raised the carriers' diabetes risk.

Each genetically predicted 1 mmol/L reduction in LDL cholesterol was associated with a 2.42-fold increased likelihood of having diabetes, based on data from 50,775 Type 2 diabetes patients and 270,269 controls, primarily from the EPIC-InterAct study, the UK Biobank study and DIAGRAM.

This equated to an additional 5.3 incident cases per 1000 person-years, say the researchers. But at the same time, these LDL cholesterol-lowering mutations reduced the risk of CAD, with each 1 mmol/L reduction being associated with a 39% lower risk among 60,801 CAD patients and 123,504 controls.

Wareham and team also looked at other lipid-lowering drug targets, finding that each 1 mmol/L reduction in LDL cholesterol conferred by mutations linked to the statin target HMGCR was associated with a 1.39-fold increased diabetes risk and a 38% decreased CAD risk, consistent with outcomes in patients treated with statins.

And the team also found a 1.19-fold increased diabetes risk associated with LDL cholesterol-lowering mutations linked to PCSK9, along with a 40% CAD risk reduction, suggesting that treatment with PCSK9 inhibitors could also result in an elevated diabetes risk.

But the researchers advise a cautious interpretation, given the relatively low statistical significance (p=0.03) and multiple comparisons.

Of note, whereas the magnitude of reduction in CAD risk conferred by genetically determined LDL cholesterol reduction was the same regardless of the gene involved, the increase in diabetes risk varied, "which would be consistent with the mediation of their associations by different mechanisms."

This, "in turn might suggest that the adverse consequences of lipid-lowering agents on diabetes risk could be specific to a particular drug target", write Wareham et al.

"This may have clinical implications for the future of lipid-lowering therapy in the context of the increasing number of approved drugs acting on different molecular targets", they say, noting that doctors could choose lipid-lowering drugs based partly on patients' personal risk of diabetes.

Original research was published in Original research was published in JAMA 2016.


3. Useful Links

Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

  

 

4. Calcium Absorption Test

EZorb Calcium has set a new world record of absorption rate. You can compare EZorb with other calcium supplements by using the simple step-by-step instructions we provide. E-mail your request to test @ elixirindustry.com for a copy of the instructions.

 

 

5. What Are Others Saying About EZorb and Marvlix?

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

     Back to EZorb Newsletter Index

  Copyright 2016 Elixir Industry